职称：教授
学历：博士
E-mail：zhuhaichuan@hbut.edu.cn
研究方向：血液肿瘤与细胞治疗
个人简介：
祝海川，bwi437官网教授，硕\博士生导师，北京大学博士，湖北省杰青，湖北省楚天学者，武汉东湖高新“3551”光谷创新人才, “3551”光谷青年人才，湖北省博士后优秀人才跟踪支持计划入选者。主要研究方向为血液肿瘤的形成、维持机制及CAR-T肿瘤免疫治疗新技术的开发及产业化。主持国自然面上基金、国自然青年科学基金C类和湖北省青年基金A类等基金。担任Journal of Translational Internal Medicine、Medicine Bulletin和Cancer Innovation等期刊青年编委及Experimental Hematology & Oncology 等杂志审稿人。截至目前以通讯作者（含共同）发表包括Nature immunology, Cell metabolism, Nature Cancer, Cell research, Journal of Hematology & Oncology (×2), Molecular therapy等论文40余篇，总引用超2000次，授权专利10项，参与完成产业转化项目3项，主导研发、申报并获批anti-CD99 CAR-T细胞注射液IND I类新药批。
教育及工作经历：
2025.07-至今 bwi437官网 437必赢会员中心 教授博士生导师
2019.07-2025.06武汉科技大学 生命科学与健康学院 博士后、副教授
2014.09-2019.07北京大学前沿交叉研究院整合生物学（导师：吴虹教授）博士
2010.09-2013.07湖北大学生命科学学院 生物化学硕士
2006.09-2010.07武昌理工学院生命科学学院生物工程学士
近五年主要获奖：
1. 第十四届“挑战杯”中国大学生创业计划竞赛，国家金奖，1/4，2024
2. 第十三届“桃战坏”中国大学生创业计划竞赛，国家银奖，1/4，2023
3. 中国国际大学生创新大赛，全国铜奖，1/4，2024
4. 发明创业成果奖，省部级，二等奖，3/5，2024
5. 中国国际大学生创新大赛，高教主赛道，省级金奖，1/4，2024
6. 湖北省第十二届“挑战杯·中国银行”大学生创业计划竞赛，省级金奖，1/4，2023
7. 数字中国创新大赛·智慧医疗赛道华中赛区决赛，省赛一等奖，1/1, 2021
8. 科创中国·湖北科技经济融合优秀项目，二等奖，排名第二，2023
9. 科创中国·湖北科技经济融合优秀项目，三等奖，排名第二，2023
近年完成的主要论文(#共同第一作者, *通讯作者)：
1. Long Chen#, Anqi Ren#, Hangyu Chen, Qifang Wu, Yuan Zhao, Zijian zhang, Tongcun Zhang, Wu Zhong*, Jian Lin*, Haichuan Zhu*, Direct inhibition of dioxygenases TET1 by the rheumatoid arthritis drug auranofin selectively induces cancer cell death in T-ALL. Journal of Hematology & Oncology. 2023.16(1):113. (IF=40.4).
2. Jiangzhou Shi#, Zijian Zhang#, Hong Cen#, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin, Kunyu Yang, Tongcun Zhang*,Haichuan Zhu*. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.Journal of Hematology & Oncology. 2021.14, 162 . (IF=40.4).
3. Zijian Zhang，Qifang Wu，Anqi Ren，Qian Chen，Jiangzhou Shi，Jiapeng Li，Xiyu Liu，Zhijie Zhang，Yuzhe Tang，Yuan Zhao，Ningning Yao，Xiaoyu Zhang，Changpeng Liu，Ge Dong，Jiaxuan Zhao，Meijun Xu，Yunqiang Yue，Jia Hu，Fan Sun，Yu Liu，Qilin Ao，Fuling Zhou，Hong Wu，Tongcun Zhang*，Haichuan Zhu*.ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming.Acta Pharmacologica Sinica.2023.1-14. (IF=8.4).
4. Yishuang Sun#, Zijian Zhang#, Haiou Li#, Xia Bu#, Li Chen#, Xiyong Wang, Lijun，Kong, Panpan Dai, Wenjing Song, Xiangling Xiao, Jie Shi, Bolin Xiang, Chuan He.GYingmeng Yao, Wenjun Xiong, Haisheng Yu, Congqing Jiang, Hudan Liu, Sufang Tian, Guoliang Qing, Zhiyong Yang, Wenyi Weis*, Gordon J. Freeman*, Haichuan Zhu*, Jinfang Zhang*. Destruction of VISTA by TRlM25 ablation in T cells potentiates cancer immunotherapy. Cell research.2025.1-18 (IF=25.9).
5. Jie Cheng#,Yifeng Xiao#, Ting Peng#, Zijian Zhang#, You Qin#, Yuqian Wang, Jiangzhou Shi, Jinxin Yan, Zihao Zhao, Liangtao Zheng, Zhijun He, Jianwei Wang, Zemin Zhang*, Cheng Li*, Haichuan Zhu*, Peng Jiang*. (2025). ETV7 limits the antiviral and antitumor efficacy of CD8+ T cells by diverting their fate toward exhaustion. Nature Cancer, 1-19. (IF=28.5）.
6. Jie Chen#, Jinxin Yan#,Ying Liu#, Jiangzhou Shi#, Haoyu Wang, Hanyang Zhou, Yinglin Zhou,Tongcun Zhang,Lina Zhao, Xianbin Meng, Haipeng Gong, Xinxiang Zhang*, Haichuan Zhu*, Peng Jiang*. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment, Cell Metabolism. 2023.35,1-18. (IF=30.9).
7. Jie Shi#, Zijian Zhang#, Hsin-Yi Chen#, Yingmeng Yao, Shanwen Ke, Kechun Yu, Jiangzhou Shi, Xiangling Xiao, Chuan He, Bolin Xiang, Yishuang Sun, Minling Gao, Xixin Xing, Haisheng Yu, Xiyong Wang,Wei-Chien Yuan,Bugi Ratno Budiarto, ShihYu Chen, Tongcun Zhang, YRu Lee*, Haichuan Zhu*, Jinfang Zhang*. Targeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR T cell therapy. Molecular Therapy. 2025. (IF=12.0）
8. Bolin Xiang#, Meiling Zhang#, Kai Li#, Zijian Zhang#, Yutong Liu, Minling Gao, Xiyong Wang, Xiangling Xiao,Yishuang Sun, Chuan He, Jie Shi, Hongzeng Fan, Xixin Xing, Gaoshan Xu, Yingmeng Yao , Gang Chen*, Haichuan Zhu*, Chengqi Yi*，Jinfang Zhang*. The epitranscriptional factor PCIF1 orchestrates CD8+ T cell ferroptosis and activation to control antitumor immunity. Nature Immunology. 2025, 1-13. （IF=27.6）
9. Yuzhe Tang#, Xiang Meng#, Xia Luo, Wentao Yao, Li Tian, Zijian Zhang, Yuan Zhao, Juan Xiao*, Haichuan Zhu*, Jia Hu*. Arginine methylation-dependent TRIM47 stability mediated by CARM1 promotes the metastasis of hepatocellular carcinoma. Cell Death Discov.2024. 10, 477 (IF=7.0)
10. Haichuan Zhu, Liuzhen Zhang, Yilin Wu, Bingjie Dong, Weilong Guo, Mei Wang, Lu Yang, Xiaoying Fan, Yuliang Tang, Ningshu Liu, Xiaoguang Lei, Hong Wu*, T-ALL leukemia stem cell'stemness'is epigenetically controlled by the master regulator SPI1. Elife. 2018;7: e38314.
